Drugs / Indium In 111-DOTA-Basiliximab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05139004 Background | Jul 2022 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indium In 111-DOTA-Basiliximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05139004 ↗ |
| Route | Intravenous | “Given IV” NCT05139004 ↗ |